Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1

Interventions

pembrolizumab 14Cisplatin 12Specimen Handling 11Magnetic Resonance Spectroscopy 7Brachytherapy 7Bevacizumab 7Radiotherapy 6atezolizumab 5Platinum 5Paclitaxel 5Nivolumab 5Human Papillomavirus DNA Tests 5Gemcitabine 5Colposcopy 5Carboplatin 5Blood Specimen Collection 5Radiation 4Fulvestrant 4lenvatinib 3Surveys and Questionnaires 3Radiation Dose Hypofractionation 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3zimberelimab 2tisotumab vedotin 2spartalizumab 2palbociclib 2X-Rays 2Topotecan 2Restraint, Physical 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Bupropion × 90 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡